Shots:

• Following the FDA Type A meeting- Gilead will not pursue the approval of Jyseleca for RA in the US. Galapagos will be solely responsible in EU for Jyseleca (200/100mg) in RA and UC + all future indications for which Gilead will receive royalties on EU sales initiating in 2024
• Galapagos to receive $194.6M- which will be split b/w $133.7M in 2021 & $60.8M in 2022 for the ongoing development and accelerated commercial buildout in the EU
• Additionally- Galapagos will assume responsibility for ongoing clinical trials evaluating filgotinib in RA. Gilead will retain commercial rights for filgotinib outside the EU- including in Japan where filgotinib has recently been approved and is co-marketed with Eisai

 ­ Ref: GlobeNewswire | Image: Canva